Litigation Details for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2020)

« Back to Dashboard

Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2020)

Docket	1:20-cv-00515	Date Filed	2020-04-15
Court	District Court, D. Delaware	Date Terminated	2020-07-28
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Parties	PURDUE PHARMA L.P.
Patents	10,369,109; 10,407,434
Attorneys	Megan Elizabeth Dellinger
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Purdue Pharma L.P. v. Intellipharmaceutics International Inc. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-04-15				External link to document
2020-04-15	1	Complaint	United States Patent Nos. 10,407,434 (the “’434 patent”) and 10,369,109 (the “’109 patent”) (collectively…RELIEF (PATENT INFRINGEMENT OF U.S. PATENT NO. 10,369,109) 53. …. This is an action for patent infringement arising under the patent laws of the United States, … that Defendants have infringed the patents-in- suit. The patents-in-suit are listed in the FDA Approved… THE PATENTS-IN-SUIT THE ’434 PATENT 37. Purdue and	External link to document
2020-04-15	14	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,407,434 B2; 10,369,109 B2. (Attachments…2020 28 July 2020 1:20-cv-00515 830 Patent None District Court, D. Delaware	External link to document
2020-04-15	3	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,407,434 B2; 10,369,109 B2. (nmg) (…2020 28 July 2020 1:20-cv-00515 830 Patent None District Court, D. Delaware	External link to document

Purdue Pharma v. Intellipharmaceutics, 1:20-cv-00515: Litigation Summary and Patent Analysis

Last updated: August 25, 2026

Purdue Pharma L.P. sued Intellipharmaceutics International Inc. in the U.S. District Court for the District of Delaware after Intellipharmaceutics submitted an abbreviated new drug application seeking approval for generic extended-release oxycodone hydrochloride tablets. Purdue asserted U.S. Patent Nos. 9,693,961 and 9,763,887, which covered abuse-deterrent oxycodone dosage-form technology associated with OxyContin. The case ended without a reported merits judgment after the parties filed a dismissal resolving the dispute. The public docket does not disclose material settlement terms. (Purdue Pharma L.P. v. Intellipharmaceutics International Inc., 2020)

What was Purdue Pharma v. Intellipharmaceutics about?

The case was a Hatch-Waxman patent infringement action involving generic oxycodone hydrochloride extended-release tablets.

Item	Case detail
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:20-cv-00515
Plaintiff	Purdue Pharma L.P.
Defendant	Intellipharmaceutics International Inc.
Filing year	2020
Product	Oxycodone hydrochloride extended-release tablets
Regulatory pathway	ANDA under the Hatch-Waxman Act
ANDA identified in the litigation	ANDA No. 212801
Asserted patents	U.S. Patent Nos. 9,693,961 and 9,763,887
Case disposition	Dismissed after settlement-related resolution
Reported trial outcome	No merits verdict or final infringement judgment

The dispute arose from Intellipharmaceutics’ Paragraph IV certification that the Purdue patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Purdue responded by filing an infringement action under 35 U.S.C. § 271(e)(2), triggering the statutory approval stay applicable to the ANDA. (21 U.S.C. § 355(j); Purdue Pharma L.P. v. Intellipharmaceutics International Inc., 2020)

Which drug and ANDA were involved?

The litigation concerned extended-release oxycodone hydrochloride tablets, the same therapeutic category as OxyContin.

The proposed product was associated with ANDA No. 212801. The record identifies the litigation as involving multiple dosage strengths of extended-release oxycodone tablets. Oxycodone hydrochloride is a Schedule II opioid used for the management of severe pain requiring continuous, around-the-clock opioid treatment.

The commercial distinction was the abuse-deterrent formulation used in reformulated OxyContin. Purdue’s product was designed to resist crushing and other physical manipulation that could facilitate rapid release or non-oral abuse. A generic applicant seeking approval had to address both the active pharmaceutical ingredient and the formulation’s release and abuse-deterrence characteristics.

What patents did Purdue assert?

Purdue asserted two patents:

Patent	Issue date	Core subject matter	Nominal expiration
U.S. Patent No. 9,693,961	June 27, 2017	Abuse-deterrent dosage forms and controlled-release opioid formulations	March 15, 2025
U.S. Patent No. 9,763,887	September 19, 2017	Related abuse-deterrent controlled-release dosage-form technology	March 15, 2025

The patents were directed to formulation characteristics rather than simply claiming oxycodone as a molecule. Their value was tied to the physical and release properties of the dosage form, including resistance to manipulation and controlled delivery of oxycodone.

The asserted patents were part of a broader Purdue patent estate surrounding OxyContin and abuse-deterrent opioid formulations. Other patents in the broader estate addressed controlled-release compositions, manufacturing parameters, dosage-form architecture, and related abuse-deterrence features. The two patents in this action were the patents placed directly at issue against Intellipharmaceutics’ ANDA.

Patent term dates can be affected by patent-term adjustment, patent-term extension, terminal disclaimers, and Orange Book listing practices. The March 15, 2025 date is the reported nominal term date associated with the asserted patent family.

What was the Paragraph IV issue?

Intellipharmaceutics’ ANDA included Paragraph IV certifications directed to Purdue’s listed patents. A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

Purdue’s lawsuit was therefore not based on commercial sales by Intellipharmaceutics. It was based on the statutory act of submitting an ANDA containing a Paragraph IV certification. Under the Hatch-Waxman framework, that submission creates an artificial act of infringement permitting the patent holder to sue before commercial launch. (35 U.S.C. § 271(e)(2))

The litigation would have required the court to assess:

1. Whether the generic formulation fell within the asserted patent claims.
2. Whether the claims were invalid for anticipation, obviousness, lack of written description, lack of enablement, or other statutory grounds.
3. Whether Purdue’s patents were enforceable.
4. Whether the generic product’s manufacturing and formulation process implicated the asserted claims.
5. Whether any settlement restricted the timing or conditions of generic entry.

The public disposition did not produce a reported claim-construction ruling, summary-judgment decision, trial opinion, or Federal Circuit decision.

What was the FDA regulatory status of the generic product?

The litigation indicates that Intellipharmaceutics had submitted ANDA No. 212801 and delivered the required Paragraph IV notice to Purdue. The filing of the patent case activated the 30-month stay framework under the Hatch-Waxman Act unless the litigation was resolved earlier or the stay was otherwise altered. (21 U.S.C. § 355(j)(5)(B)(iii))

The public case record does not establish that the FDA approved Intellipharmaceutics’ product for commercial marketing. It also does not establish that the product launched before the case was dismissed.

The regulatory outcome must be separated from the patent outcome:

• The patent case was terminated.
• The public docket does not show a merits finding that the patents were invalid.
• The docket does not establish a commercial generic launch.
• The docket does not disclose whether FDA approval was ultimately granted, withheld, or abandoned.

What was the litigation timeline?

Date or period	Event
Before April 2020	Intellipharmaceutics submitted ANDA No. 212801 and provided a Paragraph IV notice concerning Purdue’s listed patents.
April 2020	Purdue filed the District of Delaware action.
2020	The parties litigated the ANDA-related patent dispute under the Hatch-Waxman framework.
Late 2020	The parties resolved the case through a settlement-related dismissal.
After dismissal	No public merits judgment, claim-construction ruling, or trial verdict was entered in the action.

The case was dismissed before producing a judicial determination on infringement or patent validity. The public docket does not disclose the agreed generic-entry date, payment provisions, licensing rights, supply arrangements, or other settlement economics.

How strong was Purdue’s patent position?

Purdue’s position was commercially meaningful but legally untested in this particular case.

Technical strength

The asserted patents were formulation patents directed to abuse-deterrent and controlled-release features. Formulation claims can create a significant barrier when the generic applicant must replicate the reference product’s release profile and satisfy FDA requirements for pharmaceutical equivalence and bioequivalence.

The patents did not depend solely on ownership of oxycodone. They targeted product characteristics that could limit design-around options, particularly where the generic applicant sought approval for a formulation materially similar to OxyContin.

Legal strength

The case ended without a validity or infringement ruling. No public decision in this action establishes that either patent was valid, enforceable, or infringed.

The patents’ proximity to their nominal March 2025 expiration date also reduced the remaining litigation period. A successful challenge could have enabled earlier generic entry, while a successful Purdue case could have preserved the listed patents until expiration or until a negotiated entry date.

Commercial strength

The patents had greater value before expiration because they protected a high-revenue branded opioid product against ANDA competition. Their value declined as:

• The remaining patent term shortened.
• Other generic oxycodone products competed in the opioid market.
• OxyContin prescriptions faced restrictions and declining utilization.
• Purdue’s bankruptcy and restructuring affected the company’s ability to monetize and enforce its assets.

What formulation patents protected OxyContin?

OxyContin’s patent protection extended across several categories:

Abuse-deterrent formulation patents

These patents covered dosage forms designed to resist crushing, grinding, dissolving, or other manipulation. The asserted patents in this case fell within this category.

Controlled-release composition patents

Other Purdue patents addressed the release of oxycodone over an extended period. These claims could cover the matrix, excipient system, active-ingredient distribution, or release characteristics.

Manufacturing and processing patents

Manufacturing-related protection can cover mixing, granulation, compression, coating, curing, or other steps used to achieve the final abuse-deterrent properties. These rights can complicate generic development even when the final product’s composition appears similar.

Method-of-use patents

Opioid patents may also claim dosing methods, treatment methods, or use of an extended-release formulation in specific patient populations. Such patents can be listed in the Orange Book when they meet FDA listing requirements, although their effect on generic launch depends on the product labeling and the applicant’s certification strategy.

The Purdue v. Intellipharmaceutics complaint focused on the formulation patents identified in the action. The public docket does not show a separate adjudicated method-of-use dispute in this case.

What was the Orange Book status of the Purdue patents?

The asserted patents were associated with Purdue’s OxyContin patent listings and were used as the basis for the Paragraph IV dispute involving ANDA No. 212801.

Orange Book-listed patents can delay approval of an ANDA through the statutory 30-month stay after a timely infringement action. The listing does not establish that a patent will survive invalidity challenges or that the proposed generic product infringes. It establishes the regulatory and litigation pathway under the Hatch-Waxman Act. (U.S. Food and Drug Administration, 2024)

The case illustrates the commercial function of Orange Book listings: Purdue used listed formulation patents to require Intellipharmaceutics to litigate before FDA approval could proceed without the statutory stay consequences.

Did the case involve biosimilar risk?

No. Biosimilar law was not implicated.

Oxycodone hydrochloride is a small-molecule active ingredient, and Intellipharmaceutics pursued an ANDA rather than a biologics license application under the Public Health Service Act. The relevant competitive threat was generic substitution, not biosimilar substitution.

The applicable framework was:

• 21 U.S.C. § 355(j)
• Paragraph IV certification
• 30-month FDA approval stay
• ANDA patent litigation under 35 U.S.C. § 271(e)(2)

Which companies were challenging Purdue’s OxyContin exclusivity?

The Intellipharmaceutics case was part of broader generic pressure on OxyContin and other extended-release oxycodone products. Generic opioid manufacturers commonly challenged branded patents through Paragraph IV certifications or entered the market after patent expiration.

The competitive risk came from:

• Generic extended-release oxycodone tablets.
• Alternative extended-release opioid products.
• Immediate-release oxycodone products.
• Other abuse-deterrent opioid formulations.
• Reduced opioid prescribing and regulatory restrictions.

The public record for this particular action does not establish the identity of all companies that challenged the same Purdue patents, nor does it establish that Intellipharmaceutics launched an approved product.

Was there a Purdue-Intellipharmaceutics settlement?

The case ended through a dismissal associated with settlement. The public docket does not provide material settlement terms.

There is no reported public determination of:

• A specific generic launch date.
• A license grant.
• An authorized-generic arrangement.
• A payment from Purdue to Intellipharmaceutics.
• A supply agreement.
• A manufacturing restriction.
• A no-challenge provision.
• A royalty rate.

The absence of a merits judgment means the settlement did not clarify how the District of Delaware would have interpreted the asserted claims or evaluated the Paragraph IV defenses.

What litigation risks remained after dismissal?

The dismissal removed the active case but did not necessarily resolve all commercial or regulatory risk associated with the ANDA.

Potential remaining issues included:

• FDA approval timing for ANDA No. 212801.
• Whether the generic product could launch before or after the March 2025 patent term.
• Whether other Purdue patents remained relevant.
• Whether a settlement imposed confidential launch restrictions.
• Whether Intellipharmaceutics continued pursuing the ANDA.
• Whether Purdue or successor entities pursued related enforcement actions.

The most important limitation for market analysis is that the docket does not disclose the settlement’s commercial terms. The case therefore cannot be used alone to establish a firm generic-entry date.

How does this case affect revenue exposure?

The litigation exposed Purdue’s OxyContin franchise to generic erosion. A successful Paragraph IV challenge could have accelerated substitution and reduced branded revenue before the asserted patents expired. A Purdue victory could have delayed competition, but only for the remaining term of the patents and subject to other market forces.

Revenue exposure was constrained by the product’s broader commercial decline. OxyContin faced lower prescribing, opioid-related litigation, regulatory scrutiny, and the financial consequences of Purdue’s bankruptcy proceedings. The litigation’s economic importance was therefore concentrated in the remaining protected market for abuse-deterrent extended-release oxycodone rather than in a growing branded market.

The public record does not provide a case-specific revenue figure or quantify the value of the Intellipharmaceutics ANDA.

Key Takeaways

• Purdue sued Intellipharmaceutics in the District of Delaware over ANDA No. 212801 for generic extended-release oxycodone hydrochloride tablets.
• Purdue asserted U.S. Patent Nos. 9,693,961 and 9,763,887.
• The patents covered abuse-deterrent, controlled-release dosage-form technology associated with OxyContin.
• The asserted patents had a reported nominal expiration date of March 15, 2025.
• The case was a Paragraph IV Hatch-Waxman action, not a biosimilar dispute.
• The parties resolved the case through a dismissal, with no reported merits judgment.
• Public filings do not disclose the settlement’s generic-entry date or financial terms.
• The case provides no adjudicated ruling on the validity, enforceability, or infringement of the asserted patents.
• The principal commercial risk was accelerated generic erosion of OxyContin revenue.
• Any current launch-risk assessment must account for the confidential settlement, remaining Purdue patent rights, FDA status, and post-2025 patent expiration.

FAQs

Did Intellipharmaceutics launch generic OxyContin after the lawsuit?

The public case record does not establish that Intellipharmaceutics commercially launched its proposed generic product.

What was the ANDA number in the Purdue oxycodone litigation?

The litigation identified ANDA No. 212801 as the relevant abbreviated new drug application.

Were Purdue’s OxyContin patents invalidated in this case?

No. The case ended without a reported validity ruling, infringement judgment, or trial verdict.

What is the difference between OxyContin patent litigation and opioid product liability litigation?

OxyContin patent litigation concerns market exclusivity, generic approval, patent infringement, and Paragraph IV certifications. Opioid product liability litigation concerns alleged personal, governmental, or economic injuries arising from marketing, distribution, or use.

Did Purdue receive a payment from Intellipharmaceutics?

The public docket does not disclose whether either party made a payment or whether the settlement included royalties, licensing, or other economic terms.

References

1. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

2. Purdue Pharma L.P. v. Intellipharmaceutics International Inc., No. 1:20-cv-00515 (D. Del. 2020).

3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda

4. 21 U.S.C. § 355.

5. 35 U.S.C. § 271.